TAYD - テイラ―・デバイス （Taylor Devices Inc.） テイラ―・デバイスTAYDのチャート
TAYDの企業情報
| symbol | TAYD |
|---|---|
| 会社名 | Taylor Devices Inc （テイラ―・デバイス） |
| 分野（sector） | Capital Goods 資本財（工業製品） |
| 産業（industry） | Industrial Machinery/Components |
| 業種 | 産業機械_装置 工業（Industrials） |
| 概要 | 事業概要 テイラー・デバイセズ(Taylor Devices Inc.)は多様な機器、装置及び構造物に使用される衝撃吸収、レート制御及びエネルギー貯蔵デバイスの設計・開発・製造・販売に従事する。既存商品を製造・販売するほか、同社は新技術・先端技術製品の開発を継続している。同社は異なるアプリケーションを持つ一連の地震緩衝器、油圧緩衝器、クレーン・工業緩衝器、自己調整緩衝器、流動ダイスプリング及び振動緩衝器等の6種製品を製造し、顧客に販売する。これらの製品は米国にある同社の運営施設で製造される。平成24年5月期決算期において、同社収入の39％は米国の顧客への販売から生じ、54％はアジアの顧客への販売から生じていた。 テイラ―・デバイスは、衝撃吸収性、レ―ト制御、およびエネルギ―貯蔵装置を提供する米国企業。製品は、地震緩衝器、コンパクト緩衝装置｢Fluidicshoks｣、クレ―ン・工業用の緩衝装置、自動調整緩衝装置、液状ダイ・スプリングス(構成部品は、工具とダイスの製造に使用される)、振動緩衝装置を取り扱う。 Taylor Devices, Inc. designs, develops, manufactures, and markets shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The Company's product lines include shock absorbers, fluid dampers, shock isolators, liquid and hydropneumatic springs, crane buffers, and seismic dampers. |
| 本社所在地 | 90 Taylor Drive North Tonawanda NY 14120-0748 USA |
| 代表者氏名 | Douglas P. Taylor ダグラス・P・テイラー |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 716-694-0800 |
| 設立年月日 | 20271 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 111人 |
| url | www.taylordevices.com |
| nasdaq_url | https://www.nasdaq.com/symbol/tayd |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 1.64356 |
| 終値（lastsale） | 11.8 |
| 時価総額（marketcap） | 40842950.6 |
| 時価総額 | 時価総額（百万ドル） 38.83667 |
| 売上高 | 売上高（百万ドル） 24.36397 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 34.93927 |
| 当期純利益 | 当期純利益（百万ドル） 0.60737 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 May 2018 Taylor Devices Inc. revenues decreased 5% to $24.4M. Net income before extraordinary items decreased 74% to $607K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net income also reflects Selling general and administrative expe increase of 4% to $5.3M (expense) Miscellaneous decrease of 93% to $2K (income) Interest. |
TAYDのテクニカル分析
TAYDのニュース
Taylor Devices GAAP EPS of $0.47, revenue of $9.89M 2023/03/30 13:25:01 Seeking Alpha
Taylor Devices press release (TAYD): Q3 GAAP EPS of $0.47.Revenue of $9.89M (+61.1% Y/Y).
Taylor Devices Is A Great Company, But Trades At An Expensive Price (NASDAQ:TAYD) 2023/02/01 15:57:39 Seeking Alpha
Taylor Devices specializes in shock-absorbing devices for construction and aerospace uses, among others. See here for the business and TAYD stock outlook.
Taylor Devices: Pristine Balance Sheet Growth Potential Remain In Place (Rating Downgrade) 2023/01/16 12:15:00 Seeking Alpha
Taylor Devices is a well-established company with a high level of expertise in the shock and vibration control field. See why we are a hold on TAYD stock.
Taylor Devices GAAP EPS of $0.45, revenue of $10.5M (NASDAQ:TAYD) 2022/12/30 14:40:10 Seeking Alpha
Taylor Devices press release (NASDAQ:TAYD): Q2 GAAP EPS of $0.45.Revenue of $10.5M (+35.5% Y/Y).
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday''s Mid-Day Session 2022/12/29 18:14:27 Benzinga
Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH ) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. Quotient Limited (NASDAQ: QTNT ) shares jumped 124% to $0.5382 after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market. Baudax Bio, Inc. (NASDAQ: BXRX ) climbed 65.8% to $3.8150 after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery. Palisade Bio, Inc. (NASDAQ: PALI ) gained 52% to $2.76. Palisade Bio recently provided an update on its U.S. Phase 2 study evaluating LB1148 for the reduction in intra-abdominal adhesions in subjects following elective bowel resection. Nuwellis, Inc. (NASDAQ: NUWE ) shares climbed 40.5% to $12.88. Nuwellis announced an exclusive U.S. license and distribution agreement for SeaStar Medical Holding’s Selective Cytopheretic Device (SCD) for acute kidney injury (AKI) in children.
Taylor Devices Is A Great Company, But Trades At An Expensive Price (NASDAQ:TAYD) 2023/02/01 15:57:39 Seeking Alpha
Taylor Devices specializes in shock-absorbing devices for construction and aerospace uses, among others. See here for the business and TAYD stock outlook.
Taylor Devices: Pristine Balance Sheet Growth Potential Remain In Place (Rating Downgrade) 2023/01/16 12:15:00 Seeking Alpha
Taylor Devices is a well-established company with a high level of expertise in the shock and vibration control field. See why we are a hold on TAYD stock.
Taylor Devices GAAP EPS of $0.45, revenue of $10.5M (NASDAQ:TAYD) 2022/12/30 14:40:10 Seeking Alpha
Taylor Devices press release (NASDAQ:TAYD): Q2 GAAP EPS of $0.45.Revenue of $10.5M (+35.5% Y/Y).
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday''s Mid-Day Session 2022/12/29 18:14:27 Benzinga
Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH ) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. Quotient Limited (NASDAQ: QTNT ) shares jumped 124% to $0.5382 after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market. Baudax Bio, Inc. (NASDAQ: BXRX ) climbed 65.8% to $3.8150 after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery. Palisade Bio, Inc. (NASDAQ: PALI ) gained 52% to $2.76. Palisade Bio recently provided an update on its U.S. Phase 2 study evaluating LB1148 for the reduction in intra-abdominal adhesions in subjects following elective bowel resection. Nuwellis, Inc. (NASDAQ: NUWE ) shares climbed 40.5% to $12.88. Nuwellis announced an exclusive U.S. license and distribution agreement for SeaStar Medical Holding’s Selective Cytopheretic Device (SCD) for acute kidney injury (AKI) in children.
VIEW, REKR and AP among industrial movers 2022/12/29 17:56:23 Seeking Alpha
Gainers:Expion360 Inc. (XPON) +24%.Taylor Devices, Inc
Taylor Devices: Pristine Balance Sheet Growth Potential Remain In Place (Rating Downgrade) 2023/01/16 12:15:00 Seeking Alpha
Taylor Devices is a well-established company with a high level of expertise in the shock and vibration control field. See why we are a hold on TAYD stock.
Taylor Devices GAAP EPS of $0.45, revenue of $10.5M (NASDAQ:TAYD) 2022/12/30 14:40:10 Seeking Alpha
Taylor Devices press release (NASDAQ:TAYD): Q2 GAAP EPS of $0.45.Revenue of $10.5M (+35.5% Y/Y).
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday''s Mid-Day Session 2022/12/29 18:14:27 Benzinga
Gainers Hoth Therapeutics, Inc. (NASDAQ: HOTH ) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001. Quotient Limited (NASDAQ: QTNT ) shares jumped 124% to $0.5382 after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the Nasdaq Global Market. Baudax Bio, Inc. (NASDAQ: BXRX ) climbed 65.8% to $3.8150 after gaining over 5% on Wednesday. Baudax Bio recently announced initiation of a Phase II clinical trial evaluationg BX1000 in patients undergoing surgery. Palisade Bio, Inc. (NASDAQ: PALI ) gained 52% to $2.76. Palisade Bio recently provided an update on its U.S. Phase 2 study evaluating LB1148 for the reduction in intra-abdominal adhesions in subjects following elective bowel resection. Nuwellis, Inc. (NASDAQ: NUWE ) shares climbed 40.5% to $12.88. Nuwellis announced an exclusive U.S. license and distribution agreement for SeaStar Medical Holding’s Selective Cytopheretic Device (SCD) for acute kidney injury (AKI) in children.
VIEW, REKR and AP among industrial movers 2022/12/29 17:56:23 Seeking Alpha
Gainers:Expion360 Inc. (XPON) +24%.Taylor Devices, Inc
Taylor Devices Stock Gains On Solid 35% Revenue Growth In Q2 2022/12/29 16:08:30 Benzinga
Taylor Devices Inc (NASDAQ: TAYD ) reported second-quarter FY23 sales growth of 35% year-on-year, to $10.49 million. Net earnings for Q2 totaled $1.6 million versus $0.7 million … Full story available on Benzinga.com